Human Genome Editing in the Clinic: New Challenges in Regulatory Benefit-Risk Assessment

被引：26

作者：

Abou-El-Enein, Mohamed ^{[1
]}

Cathomen, Toni ^{[2
,3
]}

Ivics, Zoltan ^{[4
]}

June, Carl H. ^{[5
]}

Renner, Matthias ^{[4
]}

Schneider, Christian K. ^{[6
]}

Bauer, Gerhard ^{[7
]}

机构：

[1] Charite Univ Med Berlin, Berlin Brandenburg Ctr Regenerat Therapies BCRT, Berlin, Germany

[2] Univ Freiburg, Med Ctr, Inst Transfus Med & Gene Therapy, Freiburg, Germany

[3] Univ Freiburg, Fac Med, Freiburg, Germany

[4] Paul Ehrlich Inst, Div Med Biotechnol, Langen, Germany

[5] Univ Penn, Ctr Cellular Therapies, Perelman Sch Med, Philadelphia, PA 19104 USA

[6] Med & Healthcare Prod Regulatory Agcy, NIBSC, S Mimms, Herts, England

[7] Univ Calif Davis, IRC, Sacramento, CA 95817 USA

来源：

CELL STEM CELL | 2017年 / 21卷 / 04期

关键词：

TECHNOLOGIES; NUCLEASES;

D O I：

10.1016/j.stem.2017.09.007

中图分类号：

Q813 [细胞工程];

学科分类号：

摘要：

As genome editing rapidly progresses toward the realization of its clinical promise, assessing the suitability of current tools and processes used for its benefit-risk assessment is critical. Although current regulations may initially provide an adequate regulatory framework, improvements are recommended to overcome several existing technology-based safety and efficacy issues.

引用

页码：427 / 430

页数：4

共 50 条

[1] Benefit-risk assessment: industry and regulatory perspectives
[J]. Reactions Weekly, 2001, 882 (1) : 3 - 4
[2] A new framework to address challenges in quantitative benefit-risk assessment for medical products
Fu, Bo
Li, Xuefeng
Scott, John
He, Weili
[J]. CONTEMPORARY CLINICAL TRIALS, 2020, 95
[3] Implementing Benefit-Risk Assessment for the Periodic Benefit-Risk Evaluation Report
Warner, Margaret R.
Wolka, Anne M.
Noel, Rebecca A.
[J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2016, 50 (03) : 342 - 346
[4] Implementing Benefit-Risk Assessment for the Periodic Benefit-Risk Evaluation Report
Margaret R. Warner
Anne M. Wolka
Rebecca A. Noel
[J]. Therapeutic Innovation & Regulatory Science, 2016, 50 : 342 - 346
[5] Benefit-risk assessment of vaccines
Kochhar, Sonali
Izurieta, Hector S.
Chandler, Rebecca E.
Hacker, Adam
Chen, Robert T.
Levitan, Bennett
[J]. VACCINE, 2024, 42 (04) : 969 - 971
[6] Benefit-Risk Tradeoffs in Assessment of New Drugs and Devices
Kaul, Sanjay
Stockbridge, Norman
Butler, Javed
[J]. CIRCULATION, 2020, 142 (20) : 1974 - 1988
[7] Estimand in benefit-risk assessment
Ren, Xinru
Chen, X. Gregory
Seifu, Yodit
Wang, William
[J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2023, 33 (04) : 452 - 465
[8] EMA starts new benefit-risk assessment of flupirtine
[J]. Reactions Weekly, 2017, 1677 (1) : 2 - 2
[9] BENEFIT-RISK ASSESSMENT TODAY
HALL, RE
[J]. JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY, 1978, 55 (01) : 193 - 197
[10] Regulatory Challenges, Reimbursement, and Risk-Benefit Assessment
Breckenridge, A.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (02) : 153 - 154

← 1 2 3 4 5 →